Bayer in India: Intellectual Property Expropriation?
(8 pages of text)
Bayer Group needed to reassess its strategies regarding intellectual property, as well as its emphasis on research and development. The Indian government had ruled against Bayer by granting a compulsory licence to a local generic drug manufacturer that allowed them to distribute a copy of Bayer’s blockbuster cancer drug at a fraction of the original price. This ruling demonstrated that pharmaceutical innovation could not be effectively protected by conventional intellectual property rights in emerging markets. As a result, the core of the pharmaceutical industry’s business model was called into question: If ideas and inventions could not be protected, was the there any incentive for firms to innovate? Would this victory for generic drug manufacturers trigger similar rulings elsewhere? Would the prevailing patent-centric IP strategies need to be adapted to emerging markets? Or would innovator companies finally have to withdraw from markets with weak IP protection?
This case is intended for courses focusing on corporate strategy, technology management, innovation management and IP management. Primarily designed for use in MBA courses, it can also be taught in intellectual property courses in engineering or law.
- Understand the principles, functions and shortcomings of intellectual property.
- Gain insights into intellectual property regimes in emerging markets.
- Assess and evaluate strategic positioning and options in developed and emerging markets.
- Derive evasive strategies to protect IP from being expropriated.
Health Care Services
India, Large, 2012
$4.25 CAD / $4.25 USD Printed Copy
$3.75 CAD / $3.75 USD Permissions
$3.75 CAD / $3.75 USD Digital Download